Tellomak: T-Cell Lymphoma Anti-Kir3dl2 Therapy: An Open Label, Multi-Cohort, Multi-Center, International Phase Ii Study Evaluating the Efficacy and Safety of Iph4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-Cell Lymphoma

Hematological Oncology - United Kingdom

doi 10.1002/hon.40_2629